NeuroOne® Spinal Cord Stimulation Electrode Technology to be Featured at The Business of Pain Conference
NeuroOne Medical Technologies (Nasdaq: NMTC) announced that its percutaneous paddle technology for spinal cord stimulation will be featured at The Business of Pain Meeting in Nashville, TN. Dr. Sean Li, a renowned pain specialist and course director, will present on this innovative tool for lower back pain.
Dr. Li, President of the New Jersey Society of Interventional Pain Physicians and Treasurer of the American Society of Pain and Neuroscience, praised the technology as the most advanced percutaneous spinal cord stimulation electrode he has worked with. He believes it combines the benefits of surgically placed paddle electrodes with those of percutaneous placement, potentially improving treatment for chronic lower back pain patients.
NeuroOne estimates the current spinal cord stimulation market to be approximately $3 billion worldwide, citing large addressable patient populations with unmet clinical needs.
NeuroOne Medical Technologies (Nasdaq: NMTC) ha annunciato che la sua tecnologia del paddle percutaneo per la stimolazione del midollo spinale sarà presentata al Business of Pain Meeting a Nashville, TN. Il Dr. Sean Li, un rinomato specialista del dolore e direttore del corso, parlerà di questo strumento innovativo per il dolore alla schiena bassa.
Il Dr. Li, presidente della New Jersey Society of Interventional Pain Physicians e tesoriere della American Society of Pain and Neuroscience, ha elogiato la tecnologia come il più avanzato elettrodo di stimolazione del midollo spinale percutaneo con cui ha lavorato. Crede che combini i benefici degli elettrodi a paddle posizionati chirurgicamente con quelli del posizionamento percutaneo, migliorando potenzialmente il trattamento per i pazienti con dolore cronico alla schiena bassa.
NeuroOne stima che l'attuale mercato della stimolazione del midollo spinale sia di circa 3 miliardi di dollari a livello mondiale, citando ampie popolazioni di pazienti con bisogni clinici non soddisfatti.
NeuroOne Medical Technologies (Nasdaq: NMTC) anunció que su tecnología de paddle percutáneo para la estimulación de la médula espinal se presentará en The Business of Pain Meeting en Nashville, TN. El Dr. Sean Li, un renombrado especialista en dolor y director del curso, hablará sobre esta herramienta innovadora para el dolor lumbar.
El Dr. Li, presidente de la New Jersey Society of Interventional Pain Physicians y tesorero de la American Society of Pain and Neuroscience, elogió la tecnología como el electrodo de estimulación de la médula espinal percutáneo más avanzado con el que ha trabajado. Cree que combina los beneficios de los electrodos de paddle colocados quirúrgicamente con los del posicionamiento percutáneo, lo que potencialmente mejora el tratamiento de los pacientes con dolor lumbar crónico.
NeuroOne estima que el actual mercado de estimulación de la médula espinal es de aproximadamente 3 mil millones de dólares a nivel mundial, citando grandes poblaciones de pacientes con necesidades clínicas insatisfechas.
NeuroOne Medical Technologies (Nasdaq: NMTC)는 척수 자극을 위한 경피적 패들 기술이 테네시주 내슈빌에서 열리는 The Business of Pain Meeting에서 소개될 것이라고 발표했습니다. 고통의 권위자이자 코스 디렉터인 Dr. Sean Li는 허리 통증을 위한 이 혁신적인 도구에 대해 발표할 것입니다.
Dr. Li는 뉴저지 주 중재 통증 의사 협회의 회장이자 미국 통증 및 신경과학회 세무관으로 이 기술을 그가 작업한 가장 진보된 경피적 척수 자극 전극으로 평가했습니다. 그는 이 기술이 수술적으로 배치된 패들 전극의 이점과 경피적 배치의 이점을 결합하여 만성 허리 통증 환자의 치료를 개선할 수 있다고 믿습니다.
NeuroOne은 현재 척수 자극 시장이 약 30억 달러 규모라고 추정하며, 충족되지 않은 임상 요구를 가진 대규모 환자 집단을 언급했습니다.
NeuroOne Medical Technologies (Nasdaq: NMTC) a annoncé que sa technologie de paddle percutané pour la stimulation de la moelle épinière sera présentée lors de The Business of Pain Meeting à Nashville, TN. Le Dr. Sean Li, un spécialiste de la douleur reconnu et directeur de cours, fera une présentation sur cet outil innovant pour la douleur lombaire.
Le Dr. Li, président de la New Jersey Society of Interventional Pain Physicians et trésorier de l'American Society of Pain and Neuroscience, a salué cette technologie comme l'électrode de stimulation de la moelle épinière percutanée la plus avancée avec laquelle il a travaillé. Il pense qu'elle combine les avantages des électrodes à paddle placées chirurgicalement avec ceux de la pose percutanée, ce qui pourrait améliorer le traitement des patients souffrant de douleurs lombaires chroniques.
NeuroOne estime que le marché de la stimulation de la moelle épinière s'élève actuellement à environ 3 milliards de dollars dans le monde, en citant de grandes populations de patients ayant des besoins cliniques non satisfaits.
NeuroOne Medical Technologies (Nasdaq: NMTC) gab bekannt, dass seine perkutanen Paddle-Technologie zur Rückenmarkstimulation auf dem Business of Pain Meeting in Nashville, TN, vorgestellt wird. Dr. Sean Li, ein renommierter Schmerzspezialist und Kursdirektor, wird über dieses innovative Instrument für Rückenschmerzen referieren.
Dr. Li, Präsident der New Jersey Society of Interventional Pain Physicians und Schatzmeister der American Society of Pain and Neuroscience, lobte die Technologie als das fortschrittlichste perkutane Rückenmarkstimulationselektrode, mit der er je gearbeitet hat. Er ist der Meinung, dass sie die Vorteile der chirurgisch eingesetzten Paddle-Elektroden mit denen der perkutanen Platzierung kombiniert, was potenziell die Behandlung von Patienten mit chronischen Rückenschmerzen verbessert.
NeuroOne schätzt, dass der aktuelle Markt für Rückenmarkstimulation weltweit etwa 3 Milliarden Dollar ausmacht und verweist auf große Patientengruppen mit unerfüllten klinischen Bedürfnissen.
- NeuroOne's percutaneous paddle technology to be featured at a prominent pain management conference
- Endorsement from renowned pain specialist Dr. Sean Li
- Potential to improve treatment for chronic lower back pain patients
- Estimated $3 billion worldwide market for spinal cord stimulation
- None.
Minimally invasive technology would allow for percutaneous placement of a paddle electrode
Renowned pain specialist Dr. Sean Li to present on this innovative tool for lower back pain
EDEN PRAIRIE, Minn., Sept. 24, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that its percutaneous paddle technology will be featured at The Business of Pain Meeting September 26th – 29th at the Loew’s Vanderbilt Hotel in Nashville, TN.
Dr. Sean Li, course director and expert in pain management, will be presenting during the meeting. He has made extensive contributions to the field of interventional pain management through his research, clinical practice and leadership. He is currently the President of the New Jersey Society of Interventional Pain Physicians and the Treasurer of the American Society of Pain and Neuroscience.
Dr Li commented, “I believe this thin film electrode technology unlocks the full potential of a surgically placed paddle electrode while preserving the benefits of a percutaneous placed electrode. This is the most advanced percutaneous spinal cord stimulation electrode I have worked with and believe it offers the best of both worlds. From my own experience, I believe it has the potential to improve the current treatment for patients suffering with chronic lower back pain.”
NeuroOne estimates the current spinal cord stimulation market to be approximately
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue, "focused on," "committed to" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the potential for NeuroOne’s technology to improve the current treatment for patients suffering with chronic lower back pain, and the size of the current spinal cord stimulation market.. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages, risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company's capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks related to our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
“Caution: Federal law restricts this device to sale by or on the order of a physician”
Contact:
800-631-4030
ir@nmtc1.com
FAQ
What is NeuroOne's new spinal cord stimulation technology?
Who will present NeuroOne's (NMTC) technology at The Business of Pain Meeting?
What is the estimated market size for spinal cord stimulation according to NeuroOne (NMTC)?
When and where will The Business of Pain Meeting featuring NeuroOne's (NMTC) technology take place?
